Lannie Ho

Jun 29, 2023 | onlinelibrary.wiley.com | Jaidyn Muhandiramge |Vivian Lee |Monica Tran |Lannie Ho

Abstract Coadministration of ferric carboxymaltose and denosumab may cause hypocalcaemia and hypophosphataemia; however, this interaction is not well-described in the literature and has typically been described in patients with chronic kidney disease (CKD). We present a case of this interaction in a patient without preexisting CKD. We suggest the use of alternative iron preparations and an interval of at least 4 weeks between administrations.